Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS

60 Degrees Pharmaceuticals, Inc. SXTP

4 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.0M
▲ 65.5% YoY
$-7.4M
$-7.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. 60 Degrees Pharmaceuticals, Inc. is a Delaware corporation that was incorporated on June 1, 2022. We also operate one subsidiary. We own 97% equity in 60P Australia Pty Ltd, a Sydney, Australia-based subsidiary (“60P Australia”). 60P Australia holds sub-licensing rights for several ex-U.S. territories for our product.

Written from the business description in 60 Degrees Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth

USD 1.0M
Revenue, FY2025 · full 4-year series below
Revenue $M Net income $M
FY2025 · Revenue 1.0 · Net income -7.4
0.5M1.0M-3.0M-6.0M
20222025
Compound annual growth
+65.2%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−733 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -771.6% · Net -732.8%
-1000%-2000%
202220232025
ROE
FY2025 · ROE -196.4%
-50%-100%-150%
202220232025
Three returns, three denominators.

Each USD of equity lost 196 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -7.0
-2.5M-5.0M
202220232025

Total assetsUSD 5.4M
EquityUSD 3.5M
CashUSD 1.5M
Gross debtUSD 152,775.00
Net debtUSD -1.4M
Current ratio2.66×

The company holds more cash than debt.

The 4-year record

4 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SXTP, 4-year financial record
Metric 2025202420232022
Revenue $B0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0◌
EPS, diluted $−11.73−74.17−59.18−2.61
Dividend / sh $◌◌◌◌
Payout % — not applicable: no dividend————
ROE %−196.4−178.5——
Shares out B0.000.000.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 20 reconciliationsAUDITED

Reconciled in 4 of the 4 fiscal years we could check. 30 checks were skipped: the balance sheet is not tagged before 2022. 15 checks were skipped: EPS is not tagged before 2022. 15 checks were skipped: revenue is not tagged before 2022.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image